Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity

Author's Avatar
Sep 02, 2020
Article's Main Image

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.